Status:
COMPLETED
A Study To Compare The Amount Of Tasocitinib (CP-690,550) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Three Different Tablet Versions Of Tasocitinib (CP-690,550)
Lead Sponsor:
Pfizer
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
21-55 years
Phase:
PHASE1
Brief Summary
In this study, a 10 mg dose of tasocitinib (CP-690,550) will be given to study subjects on three separate occasions using one of three different tablet formulations (tablet versions) each time. The am...
Detailed Description
This is a pivotal bioequivalence study for tasocitinib (CP-690,550).
Eligibility Criteria
Inclusion
- Healthy male and/or female (non-childbearing potential) subjects between the ages of 21 and 55 years, inclusive.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight for males\>50 kg (110 lbs). For females, total body weight \>45 kg (99 lbs).
- No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB).
Exclusion
- Evidence of any clinically significant illness, medical condition, or disease.
- Evidence or history of any clinically significant infections within the past 3 months.
- Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2010
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01184092
Start Date
August 1 2010
End Date
September 1 2010
Last Update
October 14 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Singapore, Singapore, 188770